Prelude Fertility and NYU Langone Health Announce Partnership Targeting Expansion of Patient Care
NEW YORK--(BUSINESS WIRE)--Oct 4, 2018--Prelude Fertility (Prelude) and NYU Langone Health announced today a partnership establishing the NYU Langone Fertility Center (Fertility Center) as the latest partner in the Prelude Network, and its largest in the Northeast.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181004005143/en/
The affiliation advances Prelude’s position as the fastest growing network of fertility centers in the U.S. It creates a stronghold in the country’s top Metropolitan Statistical Area (MSA), and one of the country’s fastest growing markets for cryopreservation (“egg freezing”). Prelude and NYU Langone will expand the Fertility Center’s geographic footprint with additional satellite locations and, with particular emphasis on egg freezing, outreach to Millennials to help them take greater control of their fertility until they are ready to have a baby.
The partnership will also benefit egg donors and recipients by expanding MyEggBank, a division of Prelude and one of the largest frozen donor egg banks in North America. Specifically, it will amplify synergies with the Fertility Center’s Egg Donor Program, matching donors with patients who are unable to use their own eggs because of age, illness, genetic abnormalities, or other factors.
“It is an honor for us to affiliate with NYU Langone Health and its Fertility Center, both world-renowned for best-in-class medical services and unparalleled scientific discovery,” said Prelude Fertility’s Chief Executive Officer, Susan Hertzberg. “This innovative partnership will help change many more lives through expanded geographic reach and enhanced relevance among candidates for fertility preservation.”
“NYU Langone’s Fertility Center has long been at the forefront in fertility-related scientific discovery and care delivery,” says Andrew W. Brotman, MD, Senior Vice President and Vice Dean for Clinical Affairs and Strategy and Chief Clinical Officer at NYU Langone Health. “We’re delighted that this new agreement with Prelude allows us to significantly expand our exceptional scope of services to benefit the growing number of people seeking assistance in having a child.”
Since 1992, the NYU Langone Fertility Center has treated thousands of women and men hoping to start or expand their families. It has completed nearly 30,000 egg retrievals, including almost 4,000 for cryopreservation, resulting in more than 11,000 babies. Of these babies, over 200 were from previously frozen eggs.
The Fertility Center began its work in cryopreservation clinical trials in the 1990s, advancing and improving methodology for human application. Patients were offered free egg freezing in a trial that proved similar birth rates using frozen eggs to that of standard IVF. The Fertility Center also pioneered technologies used for preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS) to further improve the success of IVF resulting in a healthy baby, and reducing their risk of miscarriage.
The team is comprised of internationally recognized board-certified reproductive endocrinologists, under the leadership of James Grifo MD, PhD, Co-Founder and Program Director of the NYU Langone Fertility Center, and Director of the Division of Reproductive Endocrinology at NYU Langone Health. It also includes Alan Berkeley, MD; Frederick Licciardi, MD; Elizabeth Fino, MD; Brooke Hodes-Wertz, MD, MPH; Lisa Kump-Checchio, MD; and Susan Maxwell, MD. David Keefe, MD, the Stanley H. Kaplan Professor and Chairman of Obstetrics and Gynecology at NYU Langone, is also a board-certified reproductive endocrinologist and a key member of the NYU Langone Fertility Center. World-class embryologist, Caroline McCaffrey, PhD, HCLD serves as the center’s Laboratory Director.
The Fertility Center currently operates two locations in Manhattan, NY and satellites in Greenwich, CT, Stamford, CT and Tuckahoe, NY. These satellite locations are staffed by expert reproductive endocrinologists Barry Witt, MD, Anate Aelion Brauer, MD, Laura Meyer, MD, and Nora Miller, MD. Additional locations will be announced for the New York metro area.
“My colleagues and I have worked for more than a quarter of a century to help patients who haven’t yet achieved their dream of starting a family,” said Dr. Grifo. “Partnering with Prelude allows us to greatly expand our work with other top-tier centers, and to leverage the strengths of this national network to further revolutionize patient care with new access to proven treatment protocols and an expanded focus on fertility preservation.”
About Prelude Fertility
Prelude was founded in 2016 with the singular mission of helping people ensure their best chances of having a healthy baby when they are ready. The company has become the fastest-growing network of fertility centers in the U.S., providing comprehensive fertility care with the latest science and medicine to help patients achieve their family-building goals. Through the Prelude Network, patients can receive egg freezing and IVF services, genetic testing of embryos, egg donation services, and egg and embryo storage — all delivered with the highest level of personalized care by the nation’s leading reproductive endocrinologists, embryologists and practitioners. www.PreludeFertility.com
About NYU Langone Health:
NYU Langone Health is a world-class, patient-centered, integrated academic medical center, known for its excellence in clinical care, research, and education. It comprises more than 200 locations throughout the New York area, including five inpatient locations, a children’s hospital, three emergency rooms and a level 1 trauma center. Also part of NYU Langone Health is the Laura and Isaac Perlmutter Cancer Center, a National Cancer Institute–designated cancer center, and NYU School of Medicine, which since 1841 has trained thousands of physicians and scientists who have helped to shape the course of medical history. For more information, go to www.NYULangone.org, and interact with us on Facebook, Twitter, YouTube, and Instagram.
View source version on businesswire.com:https://www.businesswire.com/news/home/20181004005143/en/
Steve Schonberg, 917-717-0207
KEYWORD: UNITED STATES NORTH AMERICA NEW YORK
INDUSTRY KEYWORD: STEM CELLS HEALTH BIOTECHNOLOGY CLINICAL TRIALS GENETICS RESEARCH SCIENCE MANAGED CARE
SOURCE: Prelude Fertility
Copyright Business Wire 2018.
PUB: 10/04/2018 08:02 AM/DISC: 10/04/2018 08:02 AM